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Abstract
Gangliosides are important players for controlling neuronal function and are directly involved in AD pathology. They are
among the most potent stimulators of Ab production, are enriched in amyloid plaques and bind amyloid beta (Ab).
However, the molecular mechanisms linking gangliosides with AD are unknown. Here we identified the previously unknown
function of the amyloid precursor protein (APP), specifically its cleavage products Ab and the APP intracellular domain
(AICD), of regulating GD3-synthase (GD3S). Since GD3S is the key enzyme converting a-t ob-series gangliosides, it therefore
plays a major role in controlling the levels of major brain gangliosides. This regulation occurs by two separate and additive
mechanisms. The first mechanism directly targets the enzymatic activity of GD3S: Upon binding of Ab to the ganglioside
GM3, the immediate substrate of the GD3S, enzymatic turnover of GM3 by GD3S was strongly reduced. The second
mechanism targets GD3S expression. APP cleavage results, in addition to Ab release, in the release of AICD, a known
candidate for gene transcriptional regulation. AICD strongly down regulated GD3S transcription and knock-in of an AICD
deletion mutant of APP in vivo, or knock-down of Fe65 in neuroblastoma cells, was sufficient to abrogate normal GD3S
functionality. Equally, knock-out of the presenilin genes, presenilin 1 and presenilin 2, essential for Ab and AICD production,
or of APP itself, increased GD3S activity and expression and consequently resulted in a major shift of a-t ob-series
gangliosides. In addition to GD3S regulation by APP processing, gangliosides in turn altered APP cleavage. GM3 decreased,
whereas the ganglioside GD3, the GD3S product, increased Ab production, resulting in a regulatory feedback cycle, directly
linking ganglioside metabolism with APP processing and Ab generation. A central aspect of this homeostatic control is the
reduction of GD3S activity via an Ab-GM3 complex and AICD-mediated repression of GD3S transcription.
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Introduction
Alzheimer’s disease (AD) is a devastating neurodegenerative
disorder, pathologically characterized by extracellular senile
plaques and intracellular neurofibrillary tangles [1]. Major
constituents of senile plaques are 40–42 amino acids (aa) long
peptides termed b-amyloid (Ab) [2]. Ab is generated by sequential
processing of the type-I transmembrane amyloid precursor protein
(APP), involving b-secretase BACE1 [3] and c-secretase. The b-
secretase cleaves APP within the extracellular/luminal domain,
generating the N-terminus of Ab and a 99 aa long membrane-
bound C-terminal fragment C99/b-CTF, which is further cleaved
by c-secretase to release Ab and the APP intracellular domain
(AICD). The c-secretase consists of at least four proteins,
presenilin 1 (PS1), presenilin 2 (PS2), nicastrin, anterior phar-
ynx-defective 1 (Aph-1) and presenilin enhancer 2 (Pen-2) [4]. The
polytopic transmembrane proteins presenilin (PS) constitute the
active site of the protease [5] and mutations in the genes encoding
PS1 and PS2 are responsible for most cases of familial early-onset
Alzheimer’s disease (EOAD) [6]. As the c-secretase cleavage site is
centered within the transmembrane domain, lipid composition of
cellular membranes has been shown to influence proteolytic
processing of APP [7,8,9,10,11,12]. Beside cholesterol and
sphingomyelin (SM) [8,10], there are several strong indications
which point towards an important role of gangliosides in AD
pathogenesis [13,14,15,16]. Gangliosides are a family of sialic acid
containing glycosphingolipids, highly enriched in neuronal and
glial membranes, where they play important roles for develop-
ment, proliferation, differentiation and maintenance of neuronal
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28tissues and cells [17]. The ganglioside GM3 serves as a common
precursor for the a- and b-series gangliosides. The GD3-synthase
(GD3S) catalyzes the synthesis of GD3 by adding sialic acid to
GM3, segregating the a- and b-series of gangliosides (Fig. 1A) [18]
and therefore controlling the levels of the major brain gangliosides
GM1, GD1a, GD1b and GT1b. Gangliosides are directly involved
in AD pathology, e.g. the concentration and composition of
gangliosides are altered in the brains of AD patients and in
transgenic mouse models of AD [19,20,21]; ganglioside clusters in
neuronal membranes take part in the formation of amyloid fibrils
[13,15,16]; GM1 drastically increases Ab production [22], binds
to Ab and is discussed to act as a seed for Ab aggregation in
amyloid plaques [23,24,25]; and Ab aggregation as well as Ab
induced cell death are reduced in AD-model mice lacking GD3S
[14]. The underlying mechanism of how APP processing and AD
interfere with ganglioside homeostasis, however, remains unclear.
Here we identified a regulatory cycle in which gangliosides
regulate APP processing, and Ab and AICD control the a/b-series
ganglioside homeostasis. Central to this homeostatic control is the
regulation of the GD3S activity via an Ab-GM3 complex and
AICD mediated repression of GD3S transcription.
Results
GD3-synthase is affected in PS- and APP-deficient cells
To investigate a potential role of PS as the active part of the c-
secretase complex in ganglioside metabolism, we analyzed PS1/
PS2-deficient mouse embryonic fibroblasts (MEF PS1/2-/-)
[26,27] and PS1 wild-type retransfected control cells (MEF
PS1r) (Fig. S1). Lipid extraction of the major brain gangliosides
[28] followed by thin-layer chromatography (TLC) analysis
showed an increase in b-series gangliosides GD3, GD1b and
GT1b in PS-deficient cells, whereas levels of the a-series
gangliosides GM3, GM1 and GD1a were strongly decreased
(Fig. 1B, Fig. S2). The conversion of a-t ob-series gangliosides is
catalyzed by the enzyme GD3S, suggesting that GD3S activity is
blocked by c-secretase activity. Indeed, quantitative real-time PCR
of MEF PS1/2-/- cells showed that GD3S expression was strongly
elevated and in accordance with increased GD3S expression,
enzyme activity was also strongly increased in MEF PS1/2-/- cells
(Fig. 1C), explaining the elevated b-series gangliosides and
decreased a-series gangliosides observed. Beside c-secretase
cleavage of APP, c-secretase is involved in processing numerous
type-I transmembrane proteins [29]. To elucidate the mechanism
how PS affects GD3S activity and to identify the c-secretase
substrate involved in GD3S activity regulation, we analyzed mouse
embryonic fibroblasts devoid of APP and the APP-like protein
APLP2 (MEF APP/APLP2-/-). Similar to the results obtained
with PS-deficient cells, we observed an increase in GD3S activity
and gene transcription in MEF APP/APLP2-/- cells (Fig. 1D),
clearly suggesting that the cleavage of APP and/or APLP2 by PS/
c-secretase regulates ganglioside metabolism. Because PS knock-
out mice are not viable, the role of PS could not be directly
assessed in vivo. However, APP knock-out mice are viable, which
allowed us to evaluate the role and in vivo relevance of APP in
GD3S regulation directly. Indeed, the absence of APP alone
increased GD3S expression in the brain (Fig. 1E), providing clear
evidence for APP as a c-secretase target involved in GD3S activity
regulation.
Ab peptides decrease GD3-synthase activity by
mediating substrate availability
To identify the molecular mechanism of APP mediated GD3S
regulation, we analyzed the potential role of the APP cleavage
products Ab and AICD, which are missing in PS- or APP-deficient
cells. To identify whether Ab peptides may influence GD3S
activity, MEF PS1/2-/- and MEF APP/APLP2-/- cells were
incubated with synthetic Ab40 or Ab42 peptides at physiological
peptide concentrations. Silver stain analysis of the Ab peptides
revealed soluble monomeric Ab, but no stable small oligomers
(Fig. S3). Incubation with synthetic soluble Ab40 or Ab42 peptides
resulted in decreased GD3S activity, both in cells lacking either
PS1/2 or APP/APLP2 (Fig. 2A). To investigate whether the effect
of Ab on GD3S is due to a direct interaction, homogenates of
MEF PS1/2-/- cells and a cell-free assay, which only contained
purified GD3S and the GD3S substrate GM3, were incubated
with Ab and GD3S activity was determined. Both cell homoge-
nates and the cell-free assay showed significantly decreased GD3S
activity in presence of Ab (Fig. 2B), suggesting that decreased
GD3S activity is mediated directly by the interaction of Ab with
components of the cell-free assay. Inverted Ab peptides and
aggregated Ab had no influence on GD3S activity (Fig. 2C),
indicating a specific requirement for soluble Ab peptides as
expected for a physiological regulatory mechanism. Since Ab
peptides were able to decrease GD3S activity in a cell-free assay,
consisting only of the substrate GM3 and the enzyme GD3S, two
molecular mechanisms explaining how Ab influences GD3S
activity are conceivable: Firstly, Ab could bind to the substrate,
thus reducing substrate availability of the enzyme or secondly in
principle, Ab could directly bind to the enzyme, reducing the
turnover of GM3 to GD3. Of interest in the first context is that Ab
is known to bind to GM1, another a-series ganglioside [24].
Indeed, Ab co-immunoprecipitated GM3, the substrate for GD3S,
but interestingly, it did not bind GD3, the product of GD3S
(Fig. 2D, Fig. S4A, S4B). In agreement with our previous results we
found, using synthetic Ab40 and Ab42 peptides and the Ab40-
and Ab42-specific antibodies G2-10 and G2-11 for co-immuno-
precipitation (co-IP), that both Ab species bind GM3 (Fig. 2D; Fig.
S4C). To rule out effects caused by the use of synthetic rather than
naturally derived Ab peptides, we analyzed conditioned media of
APP expressing cells, secreting Ab40 and Ab42 in a ratio of
approximately 10:1 [30]. The experiments with conditioned media
for co-IP confirmed that naturally derived Ab40 and Ab42 bind
GM3 at a similar 10:1 ratio (Fig. 2D; Fig. S4B). As a positive
control we used GM1, which is known to bind Ab [23,24,25].
GM1 bound to both Ab species, Ab40 and Ab42 (Fig. S4D). These
experiments suggest that these GM3-Ab complexes are mecha-
nistically involved in the reduced GD3S activity we observed in
the APP or PS knock-out experiments. As already mentioned, a
second mechanism could be that Ab directly binds to GD3S and
in this way reduces the turnover of GM3 to GD3. Co-IP studies
revealed that Ab was not able to bind to GD3S in the absence of
GM3, ruling out that Ab reduces GD3 production by direct
binding to the enzyme (Fig. 2E). Importantly, under the same
experimental conditions, but in presence of GM3, Ab was bound
to GD3S (Fig. 2E). This emphasizes that the inhibition of GD3S is
mediated by binding of Ab to GM3. When the GM3-Ab complex
binds to GD3S, as indicated by Fig. 2E, the conversion of GM3 to
GD3 is reduced or prevented, consequently reducing substrate
availability. Additionally, the GM3-Ab complex might compete
with unbound GM3 for GD3S binding and therefore acts as a
competitive inhibitor, which would further reduce the amount of
GM3 available for GD3S.
AICD decreases GD3-synthase gene expression
In addition to the Ab-mediated reduction in GD3S activity, a
further mechanism of action of influencing GD3S gene transcrip-
tion, apparently exists. This is evidenced by the observation that
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e34095Figure 1. Ganglioside biosynthesis and effects on GD3s in dependence of APP-processing. (A) Biosynthetic pathway of ganglio-series
gangliosides is shown. GD3-synthase (GD3S) converts GM3 to GD3 by adding sialic acid to GM3, generating the b-series of gangliosides. The major
brain gangliosides GM1, GD1a, GD1b and GT1b are highlighted. (B) TLC analysis of a- and b-series gangliosides in PS-deficient cells. Representative
densiometric quantification of TLC, analyzing the ganglioside pattern in PS1/2 deficient mouse embryonic fibroblasts (MEF PS1/2-/-) and MEF PS1/2-/-
retranfected with PS1 wildtype (MEF PS1r). Peaks were identified by external standard and Rf-value. (C) GD3S expression and activity in PS1/2-
deficient cells. In accordance with the altered b:a ratio of gangliosides, GD3S expression and activity is increased in PS-deficient cells (MEF PS1/2-/-)
compared to MEF PS1r. (D) Analysis of GD3S activity and GD3S expression in APP/APLP2-deficient mouse embryonic fibroblasts (MEF APP/APLP2-/-)
compared to wildtype mouse embryonic fibroblasts (MEF wt). MEF APP/APLP2-/- show increased GD3S activity and enhanced corresponding GD3S
expression, analyzed by quantitative real-time PCR. (E) In vivo analysis of GD3S expression in brains of APP-deficient mice (APP-/-) show increased
GD3S gene transcription compared to wt mice.
doi:10.1371/journal.pone.0034095.g001
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mice showed elevated GD3S gene expression (Fig. 1C, D, E). In
accordance with this, Ab only partially rescued the increased
GD3S activity in PS- or APP-deficient MEF (Fig. 2A), indicating
that besides Ab other PS- and APP-dependent factors are involved
in GD3S activity regulation. The intracellular domain of APP
(AICD) is assumed to contribute to the regulation of gene
expression [31,32] comparable to the function of the Notch
intracellular domain (NICD), which is also released by c-secretase
[33]. To investigate the effect of AICD on GD3S gene expression
we analyzed APP knock-in mouse embryonic fibroblasts deficient
of full-length APP, expressing an APP construct, that lacks the last
15 aa from the C-terminus (MEF APPDCT15) and hence a
functional AICD domain [34]. The deleted last 15 aa include the
YENPTY motif of APP, which apparently plays a crucial role in
regulating gene transcription by binding to Fe65/X11 [31].
Indeed, MEF APPDCT15 cells showed increased GD3S gene
transcription and a nearly identical increase in GD3S activity
(Fig. 3A). Supporting the in vivo relevance of these findings, brains
of mice expressing APPDCT15 also showed increased GD3S
expression (Fig. 3B), which is in line with the result of APP knock-
out mice (Fig. 1E). These results indicate that the presence of
AICD strongly modulates GD3S gene transcription. To exclude
that altered Ab production, which might be caused by the
truncated APP construct APPDCT15 [35,36], could be responsi-
ble for the observed effect, we incubated MEF APPDCT15 cells
with a synthetic AICD peptide, corresponding to the last 20 aa of
the C-terminus of APP, which was applied together with SAINT-
Figure 2. Influence of Ab on GD3S activity. (A) Effect of Ab on GD3S activity. MEF lacking Ab because of PS- or APP-deficiency (MEF PS1/2-/- and
MEF APP/APLP2-/-, respectively) were incubated with physiological Ab40 or Ab42 concentrations or the solvent used for the Ab peptides (control).
The level of the GD3S activity of the corresponding wildtype cells are indicated (horizontal dotted black line); corresponding wildtype/control cells for
MEF PS1/2-/-: PS1/2 deficient MEF retransfected with PS1 (MEF PS1r); corresponding wildtype/control cells for MEF APP/APLP2: mouse embryonic
fibroblasts of wildtype mice (MEF wt). Both Ab species partially rescued the increased GD3S activity in PS- or APP-deficient MEF. No significant
differences were observed between Ab40 and Ab42 peptides. (B) Direct effect of Ab40 and Ab42 on GD3S activity. Homogenates of PS1/2-/- cells
incubated with Ab40 and Ab42 show decreased GD3S activity. Similar results are obtained with Ab40 and Ab42 in a cell-free assay containing only
purified GD3S and the substrate GM3. (C) Influence of aggregated Ab and inverted Ab on GD3S activity. Inverted Ab peptides and aggregated Ab
showed no influence on GD3S activity. (D) GM3, the substrate for GD3S, binds to Ab: Physiological concentrations of cellular derived Ab bind GM3
analyzed by co-immunoprecipitation (co-IP) of Ab in presence of GD3 or GM3. GM3, but not GD3, binds to Ab. After IP, Ab bound gangliosides were
detected via TLC. GM3 binds to synthetic Ab40 and Ab42 (shown for equimolar concentrations), and cellular derived Ab40 and Ab42 (shown for
physiological concentrations, approx. 10:1 ratio). Thin black vertical lines (Fig. 2D left) indicate that the TLC plates were scraped to separate lines. (E)
Co-IP of Ab and GD3S in dependence of GM3. Ab only binds to GD3S in presence of the substrate GM3. Data are represented as mean +/2 SEM.
doi:10.1371/journal.pone.0034095.g002
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peptide significantly decreased GD3S expression in MEF
APPDCT15 cells (Fig. 3C), validating a function of AICD in
regulating GD3S gene transcription. To further verify the role of
AICD in regulating gene expression of GD3S, we generated Fe65
knock-down cells. As expected, a 58% reduction of Fe65
expression (Fig. S5), was sufficient to almost double GD3S
expression levels (Fig. 3D).
As described above, Ab directly causes a decrease in GD3S
activity. To evaluate if, beside the observed AICD effect on gene
expression, AICD has a similar direct effect on GD3S activity,
homogenates of MEF APPDCT15 cells were incubated with
Figure 3. Effect of the APP intracellular domain (AICD) on GD3S. (A) MEF, deficient in full-length APP expressing a truncated APP construct
lacking 15 aa from the C-terminus (APPDCT15) show increased GD3S expression and activity. The level of the GD3S activity of the APP/APLP2 knock-
out cells (MEF APP/APLP2-/-) are indicated (horizontal dotted black line). Interestingly the MEF APP/APLP2 knock-out level showed a slight less effect
strength compared to the MEF APPDCT15 cells. However this difference did not reach a significant level and might be due to clonal heterogeneity. (B)
Increased GD3S expression in APPDCT15 mouse brains. (C) GD3S gene expression: AICD peptide partially rescues elevated GD3S gene expression in
MEF cells expressing the C-terminal truncated APP. An AICD peptide consisting of the last 20 aa from the APP C-terminus (AICD) is able to decrease
GD3S expression. (D) shRNA generated Fe65 knock-down cells show increased GD3S gene transcription.
doi:10.1371/journal.pone.0034095.g003
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experiment, alterations in GD3S activity cannot be caused by an
AICD-induced change in GD3S gene expression. No effect of
AICD peptide on GD3S activity was observed in these cell
homogenates, indicating that AICD has no influence on GD3S
enzymatic activity directly (Fig. S6A). Additionally, an influence of
Ab peptides on GD3S gene expression was ruled out by analyzing
GD3S expression in PS-deficient cells supplemented with Ab40 or
Ab42 (Fig. S6B).
Taken together, a dual mechanism of GD3S regulation
mediated by PS-dependent APP processing can be postulated.
Ab peptides bind to GM3, thus decreasing GD3S activity by
reducing substrate availability (Fig. 4A), whereas AICD inhibits
gene expression of GD3S (Fig. 4B). Both mechanisms synergisti-
cally result in decreased cellular GD3S activity and thus in
increased GM3 and reduced GD3 levels and an altered ratio of b:a
series gangliosides.
GM3 decreases, GD3 increases Ab production
It has been shown that the ganglioside GM1 increases Ab
production [22]. In order to analyze the effect of GM3 and GD3,
which are themselves affected by APP processing, on Ab
generation and to evaluate the presence of a potential regulatory
cycle in ganglioside homeostasis and APP processing, we
incubated COS7 cells, stably transfected with the truncated APP
construct SPC99, with GM3 or GD3. This shortened APP
construct represents the C-terminal fragment of b-secretase
cleaved APP, and allows the study of GM3 and GD3 influence
on c-secretase activity, independent of b-secretase activity [38,39].
Unexpectedly, the ganglioside GM3 decreased (Fig. 5A), but GD3
increased Ab levels (Fig. 5B). Both effects were dose-dependent in
a range from 10 to 100 mM. LDH-assay analysis revealed no signs
of elevated cytotoxicity or reduced membrane integrity in the
presence of gangliosides (Fig. S7). The effect of GM3 and GD3 is
apparently cell line independent, since we obtained similar results
in the human neuroblastoma cell line SH-SY5Y (Fig. S8).
Discussion
Gangliosides are sialic acid containing glycosphingolipids
ubiquitously present in eukaryotic membranes with numerous
cellular functions like signal transduction, cell adhesion, protein
transport and brain development [17]. The numerous functions of
gangliosides and the sequential anabolic pathway as described in
Fig. 1A suggest that these enzymes must be tightly regulated. The
major brain gangliosides belong either to the a-o rb-series of
gangliosides, emphasizing the importance of GD3S for brain
ganglioside homeostasis. Although it is well established that brain
ganglioside composition alters continuously during aging and in
AD [19,28], the underlying cellular mechanisms remain unknown.
To evaluate the link between ganglioside metabolism, APP
processing and the resulting consequence for AD pathology, we
analyzed ganglioside homeostasis for dependence on APP
processing.
Absence of either APP or PS in cells or in the corresponding
mouse models increased GD3S activity and expression, which, as a
consequence, resulted in an increase in the b-t oa-series ratio of
gangliosides. Breaking down the molecular mechanism in detail,
we identified that the regulation of GD3S by APP processing
depends on two molecular factors, Ab peptides and AICD. Ab
selectively binds GM3, the GD3S substrate, but not GD3, the
GD3S product. The GM3-Ab complex is still able to bind to
GD3S but Ab effectively prevents the conversion of GM3 to GD3,
hence resulting in lowered cellular GD3S activity. Because Ab is
secreted and taken up by cells [40,41] and since there are,
especially in neural cells, abundant amounts of Ab present
intracellularly [42,43,44], binding of Ab to GM3 could in
principle take place in any intracellular compartment, especially
along the secretory pathway and endosomes, at the plasma
membrane, where large amounts of Ab are present, as well as in
the extracellular space [45]. Selective reduction of substrate
availability by binding of the substrate to an inhibitor, often
described as substrate depletion, is a common molecular
mechanism to modulate substrate turnover. A similar mechanism
is described for phospholipids, which can be cleaved by
phospholipases (PLA2). In the presence of the protein annexin,
PLA2 activity is reduced by binding of annexin to the
phospholipids [46]. Interestingly, Ab has been observed to bind
several other lipids, such as cholesterol [47] and GM1 [24]. GM1,
another a-series ganglioside, is elevated in amyloid plaques further
strengthening the link between GD3S regulation and AD [48].
With this conditions used here neither synthetic nor naturally
derived soluble Ab bound GD3. It has previously been reported
that synthetic Ab 1–40 as well as synthetic inverted Ab 40-1 binds
to all sialylated gangliosides [49]. This might indicate that
conditions exist, such as amyloid formation as typical for AD,
under which Ab like peptides have increased affinity to all
sialylated gangliosides. In such a case, binding of GD3 to Ab,
would likely further contribute to the disturbance of the
physiological ganglioside homeostasis in the AD brain.
Reduced GM3 to GD3 turnover is further enhanced by another
Ab independent effect. Although Ab directly decreased GD3S
activity, this cannot account for the observed increase in GD3S
Figure 4. Molecular mechanisms of APP cleavage products in
the regulation of GD3S enzyme activity. (A) In absence of Ab
peptides a-series ganglioside GM3 binds to GD3S and is converted to
the b-series ganglioside GD3. In presence of Ab,A b binds ganglioside
GM3, forming an Ab-GM3 complex. This complex still binds to GD3S,
but cannot be converted to GD3. (B) Dual function of Ab and AICD in
GD3S regulation. Ab reduces enzyme activity of GD3S by forming an
Ab-GM3 complex, resulting in reduced turnover of GM3 to GD3. AICD
binds the adaptor protein Fe65 and reduces GD3S gene transcription,
which also results in reduced turnover of GM3 to GD3.
doi:10.1371/journal.pone.0034095.g004
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on GD3S expression levels. Cao and others have found that AICD
has structural and functional similarities with NICD, a well-
established regulator of gene transcription [50]. However, the
relevance of AICD for transcriptional regulation remains contro-
versial [12,31,32,50]. To elucidate whether the increased GD3S
expression is mediated via AICD, we used APPDCT15 cells
lacking the last 15 aa of the APP C-terminus and therefore a
functional AICD. MEF APPDCT15 cells showed drastically
elevated GD3S gene transcription and similarly increased GD3S
activity. Confirming the essential role of a functional AICD for
GD3S regulation, the increased GD3S expression in APPDCT15
cells could be partially rescued by addition of synthetic AICD
peptide. To further verify our results that AICD triggers a cascade
that results in decreased GD3S expression, we investigated
whether a similar effect can be obtained by eliminating another
protein from this cascade. Fe65 binds to the YENPTY motif of
AICD and mediates nuclear targeting of AICD [51]. In line with
the findings that absence of AICD causes an increase in GD3S
expression, we found in Fe65 knock-down cells increased GD3S
expression, validating the AICD/Fe65-mediated mechanism for
regulating GD3S expression. Similar to the finding that Ab altered
GD3S enzymatic activity, but not GD3S expression, AICD
suppressed GD3S expression, but had no influence on GD3S
enzymatic activity.
These findings support an essential role of APP in ganglioside
homeostasis in AD. The function of AICD, Ab and c-secretase in
regulating GD3S would suggest that the alteration in ganglioside
composition is a consequence of AD. Nevertheless, both the
substrate and product of the GD3S, GM3 and GD3, themselves
modulate APP processing making the distinction between cause
and consequence less clear. Like ganglioside GM1, GD3 increased
Ab generation whereas GM3 decreased Ab release. Glycosphin-
golipids have been shown to be implicated in the regulation of the
subcellular transport of APP in the secretory pathway [52],
indicating that altered Ab generation in presence of different
gangliosides might be caused by altered APP transport to the
cellular compartments where Ab generation preferentially occurs,
in post-Golgi secretory and endocytic compartments [45,53]. In
addition changes in lipid raft composition might alter Ab
generation. For example it has been recently shown that
docosahexaenoic acid (DHA) decreases Ab generation by
decreasing cholesterol in lipid raft membrane microdomains
[54]. The hypothesis that lipids are also important for functional
cellular protein transport as already reported for glycosphingolip-
ids by Tamboli et al. [52] is further substantiated by the finding
that BACE1 protein transport to the endosomal compartments,
where b-secretase cleavage preferentially occurs, is impaired in
presence of some lipids, e.g. DHA [54]. However, although it has
been shown that membrane lipid composition influences APP
cleavage [7,8,9,10,11], we do not exclude that lipids, such as GM3
and GD3, might directly affect secretase activities or other cellular
mechanisms involved in Ab generation. Reducing GD3S activity
as potential therapeuthic target to treat or prevent AD would
result in decreased GD3 and increased GM3 levels both resulting
in decreased Ab levels. However, one has to take into
consideration that GM3 is further converted to ganglioside
GM1, which is discussed to increase Ab generation and to induce
Ab aggregation in vitro. In opposite to the in vitro findings
concerning GM1 induced Ab aggregation, in vivo studies revealed
that GM1 is not required for Ab aggregation [55] or even
neuroprotective [14,56,57]. Disruption of the GM2 synthase gene
Figure 5. Effect of GM3 and GD3 on APP processing. (A) Dose-dependent effect of GM3 on Ab production: COS7 cells stably transfected with
SPC99, representing the b-secretase cleaved C-terminal fragment of APP, show a dose-dependent decrease in Ab production in presence of GM3. Ab
levels were determined by IP and Western blot (WB) analysis. (B) Dose-dependent effect of GD3 on Ab generation in SPC99 expressing COS7 cells.
GD3 enhances Ab generation dose-dependently. Ab levels were determined by IP and WB analysis.
doi:10.1371/journal.pone.0034095.g005
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although GM1 is completely lacking in these mice [55]. Moreover,
Bernardo et al. observed that deletion of GD3S, increasing
neuronal expression of GM1, results in reduced soluble Ab levels,
decreased Ab aggregation and plaque load in APP/PS transgenic
mice paralleled by behavioural improvements [14]. From this line
of evidence changes in the cerebral ganglioside composition might
alter Ab generation and aggregation and might be beneficial
regarding AD pathology. Additionally, a recent study from
Dhanushkodi et al. reports neuroprotective effects in vivo using
sialidase from Vibrio cholerae producing a brain ganglioside
profile similar to that of the GD3S knock-out, further implicating
GD3S as a potential therapeutic target for AD [58]. However,
further experiments are necessary to identify the role of specific
gangliosides in AD pathology.
From our findings we propose a hypothetic model showing that
GD3S and APP form a regulatory feedback cycle that links
ganglioside metabolism with APP processing (Fig. 6). Since this
regulatory cycle involves synergistic components the magnitude of
the effect can be increased. Both Ab and AICD decrease GD3S
activity, resulting in strongly decreased GD3 levels. This in turn
leads to reduced cleavage of APP. Additionally, decreased GD3S
activity results in increased GM3 levels, further reducing APP
cleavage to Ab. It can therefore be proposed that interventions
shifting the GD3/GM3 ratio towards increased GM3 and
derceased GD3 levels could, by influencing this regulatory
feedback cycle, cause reduced amyloidogenic processing of APP.
This therefore may prove to be a potential strategy to treat or
prevent AD.
Materials and Methods
Cell culture and biological material
COS7, SH-SY5Y and MEF cells were cultivated in DMEM
(Sigma, Taufkirchen, Germany), 10% FCS (PAN Biotech,
Aidenbach, Germany); for pCEP4/APP and pCEP4/SPC99
transfected cells additional HygromycinB (400 mg/ml) (PAN
Biotech, Aidenbach, Germany) [44] was used. MEF PS1/2-/-
cells were transfected with pCNA3.1/PS1 wildtype using Super-
fect as described by the manufacturer (Qiagen) to generate PS1
wildtype retransfected control cells (MEF PS1r). Stable transfec-
tants were selected using 300 mg/ml Zeocin. MEF PS1r cells were
cultivated in DMEM (Sigma, Taufkirchen, Germany), 10% FCS
(PAN Biotech, Aidenbach, Germany), 300 mg/ml Zeocin (Invitro-
gen, Karlsruhe, Germany). Stable transfection and functionality of
MEF PS1r cells were validated by PS1 western blot analysis (Fig.
S1A), Ab generation (Fig. S1B) and enzymatic measurement of c-
secretase activity (Fig. S1C). MEF PS1/2-/- cells [26,27], MEF
PS1r cells [10], MEF APP/APLP2-/- cells [59] and MEF
APPDCT15 cells [34] have been described previously.
Ganglioside (Axxora, Lo ¨rrach, Germany) exposure was carried
out in culture media without FCS for 16+6 hours. Notably the
critical micelle concentration (CMC) of gangliosides examined in
previous studies varies in dependence of the used methods.
Whereas one study reports that for all gangliosides the CMC is
between 70 to 100 mM [60], another study suggests for mono-
sialogangliosides a CMC of 8.5*10
25 M and for disialoganglio-
sides a CMC of 9.5*10
25 M [61]. In addition a more recent study
suggests an even lower CMC for ganglioside GM3 of 3.4*10
29 M
[62]. Therefore we used different ganglioside concentrations from
10 to 100 mM, which revealed a dose-dependent effect (Fig. 5).
Western Blot analysis
Ab analysis of conditioned media of cultured cells was
performed with antibody W02 as described earlier [63]. Control
experiments using antibody WO2 for Ab detection are shown in
supplement Figures S9A, S9B and S9C. For the detection of PS1,
cell-lysates were separated on 10–20% Tricine gels (Anamed,
Groß-Bieberau, Germany). Cell-lysates were generated as previ-
ously described [44]. WB analysis was performed with the
antibody sc-7860 (1:500; Santa Cruz, Heidelberg, Germany).
Densiometric quantification was performed using Image Gauge
software. Samples were adjusted to equal protein amount before
WB analysis [64].
Ganglioside determination and thin layer
chromatography
After washing confluent grown cells three times with ice-cold
phosphate-buffered saline (PBS), cells were scraped off and
homogenized using a PotterS (B. Braun, Melsungen, Germany)
at maximum speed (30 strokes). Protein amount was adjusted to
70 mg/ml according to Smith et al. [64]. After protein adjust-
ments, a modified Bligh & Dyer method [65] was used to isolate
gangliosides. After desalting the lipids via a reversed-phase
cartridge (Waters Oasis, Eschborn, Germany) according to
Whitfield et al. [66] a highly concentrated extract was applied to
silica gel thin-layer chromatography (TLC) plates (Merck,
Darmstadt, Germany). As a solvent system CHCl3/MeOH/
H2O-CaCl2 0.2% (60/35/8) was used [67]. The glycolipids were
visualized by iodine and identified by their Rf-values and
commercially available standards (AvantiPolarLipids, Alabaster,
Figure 6. Hypothetic model of the physiological functions of Ab
and AICD in the regulation of GD3-synthase (GD3S) – the
enzyme controlling major brain ganglioside composition. (A)
Amyloidogenic proteolytic processing of the Alzheimer’s amyloid
precursor protein (APP) releases amyloid-beta peptides (Ab) and the
intracellular domain of APP (AICD). Ab and AICD inhibit GD3S, resulting
in reduced conversion of a-t ob-series gangliosides. As a consequence
of reduced conversion of a-t ob-series gangliosides, GM3 increases
whereas GD3 decreases. In return, both gangliosides, GM3 and GD3,
themselves regulate the proteolytic cleavage of APP. The b-series
ganglioside GD3 increases, whereas the a-series gangliosides GM3
decreases amyloidogenic proteolytic processing of APP.
doi:10.1371/journal.pone.0034095.g006
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Gauge software. All solvents used were HPLC grade (VWR
International GmbH, Darmstadt, Germany). To validate the use
of iodine to stain gangliosides, we separated brain samples and
ganglioside standard via TLC and stained either with iodine,
orcinol or resorcinol (Fig. S10).
Determination of binding properties of Ab to
gangliosides and GD3S
Co-IP of Ab with gangliosides was carried out with Ab,
produced by SH-SY5Y cells stably transfected with APP695 or
with synthetic Ab peptides (10 ng/ml) (B. Penke, Szeged,
Hungary). For immunoprecipitation of Ab peptides bound to
gangliosides, monoclonal antibodies W02 (1 mg/ml), G2-10
(12.5 mg/ml), specific for the detection of Ab40, and G2-11
(17.3 mg/ml), specific for the detection of Ab42, were used [63].
Gangliosides bound to Ab peptides were analyzed by TLC.
Purified GD3S was purchased from Abnova (Taipei, Taiwan),
used at a final concentration of 0.5 mg/ml and detected by
silverstain [68].
Co-Immunoprecipitation of GD3S with Ab peptide and
Ganglioside GM3
13.65 nM of GD3S (Abnova, Taipei, Taiwan), 11.55 nM Ab40,
1.155 nM Ab42 were preincubated in PBS (pH 7.0, final volume
1 ml) in absence or in presence of 100 mM GM3 in a glass tube for
3 hours at 4uC with gentle shaking. After preincubation, samples
were transferred in a microcentrifuge tube and 5 mg of antibody
WO2 and 20 ml ProteinG-Sepharose were added. Immunopre-
cipitation of Enzyme-Peptide-Lipid-complex was performed over
night at 4uC on an end over end shaker. At the end of incubation
time, samples were centrifuged at 13.000 rpm for 1 min at 4uC.
Supernatant was removed and Sepharose Beads were washed
three times with 1 ml of 10 mM Tris (pH 7.4) Samples were
boiled in SDS-sample buffer (187.5 mM Tris/HCl pH 6.8, 6%
SDS, 30% Glycerol, 15% b-Mercaptoethanol 0.03% Bromphe-
nolblau) and separated on a 10–20% Tris-Tricine Gel. Proteins
were detected by silver staining according to the method of Switzer
et al. [68].
Determination of monomeric Ab40 and Ab42 by SDS
PAGE and Silver Staining
To determine the monomeric status of Ab40 and Ab42, used in
in vitro and cell culture experiments, the synthetic peptides (200 ng
Ab40+20 ng Ab42) were separated by SDS PAGE on a 12%
NuPAGE Bis-Tris gel (Invitrogen), according to Dahlgren et al.,
which were also able to detect Ab oligomers by utilizing this
method [69]. Proteins were visualized by silver stain.
Enzymatic assays
For measuring GD3S activity confluent grown cells were
washed three times with ice-cold sodium cacodylate 7.5 mM
pH 5.8 including 1.5% Triton X-100, scraped off and homoge-
nized using a PotterS (B. Braun, Melsungen, Germany) at
maximum speed (100 strokes) [70]. After protein adjustment to
25 mg the reaction was started by addition of 5 nM CMP-sialic
acid [
3H] (ARC, St. Louis, USA), 10 nM GM3 (Axxora, Lo ¨rrach,
Germany) and 50 nM CMP-sialic acid (Sigma, Taufkirchen,
Germany) in sodium cacodylate 7.5 mM pH 5.8 at 37uC. After
45 min the enzymatic reaction was stopped by addition of MeOH
and CHCl3, gangliosides were extracted as described above and
separated via TLC. The GD3-band was scraped off and the
including radioactivity was measured via scintillation counting in
Tri-Carb2800TR (Perkin Elmer, Rodgau-Ju ¨gesheim, Germany).
To determine the effect of Ab40 (10 ng/ml), Ab42 (1 ng/ml) (B.
Penke, Szeged, Hungary), inverted Ab (10 ng/ml) or AICD
(2 mM) (Genscript Corporation, Piscatway, USA) synthetic pep-
tides were incubated for 1 h to cell-lysate and for 9 days in cell
culture. After incubation the reaction was started by adding 5 nM
CMP-sialic acid [
3H] (ARC, St. Louis, USA), 10 nM GM3
(Axxora, Lo ¨rrach, Germany) and 50 nM CMP-sialic acid (Sigma,
Taufkirchen, Germany) in sodium cacodylate 7.5 mM pH 5.8 to
the preincubated GM3-Ab complex and stopped after another
45 min by addition of MeOH.
For the GD3S in vitro assay 25 nM Ab and 5 nM GM3
were preincubated for 1 h to allow the formation of the complex
GM3-Ab. After that the reaction was started by adding 5 nM
CMP-sialic acid [
3H] (ARC, St. Louis, USA), 10 nM GM3
(Axxora, Lo ¨rrach, Germany) and 50 nM CMP-sialic acid (Sigma,
Taufkirchen, Germany) in sodium cacodylate 7.5 mM pH 5.8 to
the preincubated GM3-Ab complex and stopped after another
45 min by addition of MeOH. For cell-free enzymatic assay
purified GD3S (1 mg/ml; 27.3 nM) (Abnova, Taipei City, Taiwan)
was used instead of lysate. Aggregated Ab was prepared as
22.2 mM solution by incubation .24 h at 37uC [10] and finally
used as 22.2 nM. All solvents used were HPLC grade (VWR
International GmbH, Darmstadt, Germany). GD3S assay un-
specificity was determined using ganglioside GM2 (Fig. S11).
Determination of c-secretase activity
Detection of c-activity was performed as described before
[38,54]. Briefly, cells were washed three times with ice-cold
phosphate-buffered saline (PBS), scraped off in sucrose buffer
(10 mM Tris/HCl pH 7.4 including 1 mM EDTA and 200 mM
sucrose) and homogenized using a PotterS at maximum speed (25
strokes). After protein adjustment to 1 mg according to Smith et al.
1985 [64], the samples were centrifuged at 900rcf for 10 min at
4uC and the obtained post-nuclear fractions were ultracentrifuged
at 55000 rpm for 75 min at 4uC. Pelleted membranes were
resuspended using cannulaes with decreasing diameter in 300 ml
sucrose buffer. The volume is partioned in 96well plates (c: 100 ml,
equates to 250 mg protein) and c-secretase substrate [71]
(Calbiochem, Darmstadt, Germany) (10 mM) was added. Fluores-
cence was measured for 3 h under light exclusion using excitation
at 355610 nm and fluorescence detection at 440610 nm or
34565 nm/50062.5 nm respectively. Assay specificity is .90%
for c-secretase activity assay, and was validated using c-secretase
inhibitor L-658458 (Merck, Darmstadt, Germany).
Knock-down experiments
According to the manufacturer’s protocol SureSilencing
TM
shRNA Plasmid (SABioscience, Frederick, USA) was used. The
following insert sequences were used:
Fe65: 59-TCC CTG GAC CAC TCT AAA CTT-39
59-CAA CCC AGG GAT CAA GTG TTT-39
59-AAG GCT TTG AGG ATG GAG AAT-39
59-TGT CCA CAC GTT TGC ATT CAT-39.
Control: 59-GGA ATC TCA TTC GAT GCA TAC-39.
This control was used as randomized sequence in all knock-
down experiments. The knock-down was verified by quantitative
real-time experiments.
Quantitative real-time experiments
Total RNA was extracted from cells or tissue using RNeasyPlus
Mini Kit (Qiagen, Hilden, Germany) or TRIzol reagent (Invitro-
gen, Karlsruhe, Germany), using manufacturer’s protocols. 2 mg
were reverse-transcribed using High Capacity cDNA Reverse
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carried out using Fast SYBR Green Master Mix on 7500 Fast
Real-Time PCR System (7500 Fast System SDS Software 1.3.1.;
Applied Biosystems, Darmstadt, Germany). As control RNA
samples were normalized to b-actin gene expression.
To determine the effect of Ab40 (10 ng/ml), Ab42 (1 ng/ml) (B.
Penke, Szeged, Hungary) or AICD on gene transcription (2 mM)
(Genscript Corporation, Piscatway, USA) synthetic peptides were
incubated for 9 days in cell culture. Alternatively, the compound
SAINT-2:DOPE was added together with the synthetic peptides
for 12 h to the cells to achieve efficient delivery of the peptides
[37].
Changes in gene expression was calculated using 2
2(DDCt)
method [72]. The DDCT data are shown in table S1. To verify the
results obtained by quantitative real-time experiments, samples
were separated on 1.5% agarose gels in TBE buffer (90 mM Tris,
90 mM boric acid, 2 mM EDTA pH 8.0).
The following primer sequences were used:
Fe65 pair1: 59-TCT TGC ACC AGC AGA CAG AG-39 and
59-CAG CCA TGA TGA ATG CAA AC-39;
pair2: 59- TTT GGA AGG ATG AAC CCA GT-39 and
59-AAG CTT CTC CTC CTC TTG GG-39;
pair3: 59- GCT CTA AGA TCA TGG CCG AA-39 and
59-GGA ATT CCA CTT GGA AAG GG-39.
b-Actin: 59-CCT AGG CAC CAG GGT GTG AT-39 and
59-TCT CCA TGT CGT CCC AGT TG-39.
Cytotoxicity measurement
Cytotoxicity was measured using Lactate Dehydrogenase
Cytotoxicity Assay Kit (LDH-Assay) and performed as described
in the manufacturer’s protocol (Cayman Chemical, Ann Arbor,
USA). Briefly, conditioned media of incubated cells were
centrifuged for 5 min at 400 g. 100 ml supernatant was used to
determine lactate dehydrogenase cytotoxicity levels. For each
cytotoxicity measurement lactate dehydrogenase standards were
used as described in the manufacturer’s protocol. After adding
100 ml reaction solution, the plate was agitated for 30 min at RT.
Absorbance was measured at 490 nm using a MultiskanEX plate
reader (Thermo Fisher Scientific, Waltham, USA).
Statistical analysis
All quantified data represent an average of at least three
independent experiments. Error bars represent standard deviation
of the mean. Statistical significance was determined by two-tailed
Student’s t-test; significance was set at *P#0.05; **P#0.01 and
***P#0.001, n.d.=not detectable.
Supporting Information
Figure S1 Analysis of PS1 retransfected mouse embryonic
fibroblasts devoid of PS1 and PS2. (A) PS expression in mouse
embryonic fibroblasts (MEF) devoid of PS1 and PS2 (PS1/2-/-),
corresponding wild-type embryonic fibroblasts (wt) and MEF
PS1/2-/- cells retransfected with PS1 (PS1r). Western blot analysis
of cell-lysates; PS was detected using the antibody sc-7860. (B)
Determination of Ab generation in PS1 retransfected MEF PS1/
2-/-. MEF PS1/2-/- and MEF PS1r were infected with Semliki
Forest Virus expressing APP695. Conditioned media were
collected, immunoprecipitated with antibody W02 and detected
via WB analysis using W02. (C) c-secretase activity of MEF wild-
type (wt) cells and MEF PS1r. c-secretase activity of MEF wt and
MEF PS1r was measured as described in Material and Methods.
(TIF)
Figure S2 TLC analysis of a- and b-series gangliosides in PS-
deficient cells. (A) A representative TLC, analyzing the ganglioside
pattern in PS1/2 deficient mouse embryonic fibroblasts (MEF
PS1/2-/-) and MEF PS1/2-/- retranfected with PS1 wildtype
(MEF PS1r) is shown. A ganglioside standard was loaded on the
TLC. (B) Densiometric quantification of a representative TLC.
(TIF)
Figure S3 Determination of monomeric Ab40 and Ab42 by
SDS Page and Silver staining. Synthetic Ab40 and Ab42 peptides
(200 ng Ab40, 20 ng Ab42) used for the in vitro and cell culture
experiments were loaded and separated on a 12% NuPAGE Bis-
Tris gel Proteins were visualized by silver stain.
(TIF)
Figure S4 Co-immunoprecipitation of gangliosides with Ab40
and Ab42 peptides. (A) Co-immunoprecipitation studies using
ganglioside GD3, cellular derived Ab40 and Ab42 peptides and the
Ab40 and Ab42 specific antibodies G2-10 and G2-11. Cellular
derived Ab40 and Ab42 peptides were obtained from conditioned
media of APP wildtype expressing cells. Ganglioside GD3 does not
co-immunoprecipitates with Ab40 and Ab42. (B) Co-immunopre-
cipitation studies using ganglioside GM3, cellular derived Ab40 and
Ab42 peptides and the Ab40 and Ab42 specific antibodies G2-10
and G2-11. Cellular derived Ab40 and Ab42 peptides were
obtained from conditioned media of APP wildtype expressing cells,
secreting Ab40/Ab42 peptides in a ratio of approximately 10:1.
Ganglioside GM3 co-immunoprecipitates with Ab40 and Ab42. In
accordance to the 10:1 ratio of cellular derived Ab40/Ab42
peptides, the detected GM3band shows a similar 10:1ratio. (C) Co-
immunoprecipitation studies using ganglioside GM3 and equimolar
concentrations of synthetic Ab40 and Ab42 peptides. GM3 co-
immunoprecipitates with synthetic Ab40 and Ab42 peptides. As
expected using equimolar concentrations of Ab40 and Ab42
peptides, the stained (co-immunoprecipitated) GM3 bands have
nearly identical intensity. (D) Co-immunoprecipitation studies using
ganglioside GM1 and equimolar concentrations of synthetic Ab40
and Ab42 peptides. Black dotted vertical line: Samples were loaded
on the same TLC but were not next to each other.
(TIF)
Figure S5 Fe65 knock-down in human neuroblastoma SH-
SY5Y cells. The Fe65 expression level measured by RT-PCR
analysis was reduced to 42%. Corresponding agarose gel is shown.
(TIF)
Figure S6 Influence of AICD on GD3S activity and of Ab
peptides on GD3S expression. (A) AICD peptides were incubated
on APPDCT15 cell homogenates and GD3S activity was
determined as described. (B)A b peptides (Ab40 and Ab42) were
incubated in cell culture on MEF PS1/2-/-. GD3S expression was
determined by RT-PCR.
(TIF)
Figure S7 Lactate dehydrogenase assay in cells incubated with
100 mM GM3 or 100 mM GD3 versus corresponding solvent
control (ddH2O). No signs for increased cytotoxicity were
observed in cells treated with gangliosides.
(TIF)
Figure S8 Ab production in SPC99 expressing SH-SY5Y cells
incubated with GM3 and GD3. Cells were incubated with
100 mM GM3 and 100 mM GD3, respectively, versus correspond-
ing solvent control (ddH2O). Conditioned media were collected
and immunoprecipitated with the antibody W02. WB analysis was
performed using the antibody W02.
(TIF)
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detection. (A) 5 ng, 10 ng, 20 ng and 40 ng of synthetic Ab40 and
Ab42 peptides, respectively, were loaded and separated on Tris-
Tricine gels. Western blot (WB) analysis to detect Ab was
performed with antibody WO2. (B) Human neuroblastoma SH-
SY5Y cells were incubated with 2 mM c-secretase inhibitor X
(Calbiochem, Darmstadt, Germany) and the solvent control.
Conditioned media were immunoprecipitated with antibody
WO2. Immunoprecipitated proteins were loaded and separated
on a Tris-Tricine gel and detected via WB analysis using antibody
WO2. In presence of c-secretase inhibitor, Ab cannot be detected
(negative control). (C) Human neuroblastoma SH-SY5Y cells were
incubated with 100 mM GM1 and the solvent control. Condi-
tioned media were immunoprecipitated with antibody WO2.
Immunoprecipitated proteins were loaded and separated on a
Tris-Tricine gel. WB analysis was performed with antibody WO2.
GM1 increases Ab generation (positive control).
(TIF)
Figure S10 Staining of gangliosides separated via TLC using
iodine, orcinol and resorcinol. Brain samples and ganglioside
standard were separated via TLC as described in the material and
method section and stained with iodine, orcinol and resorcinol.
TLC1 was first stained with iodine and afterwards with orcinol.
TLC2 was first stained with iodine and afterwards with resorcinol.
This analysis shows that gangliosides (GM3, GM1, GD3, GD1a,
GD1b and GT1b) can be stained with iodine, orcinol and resorcinol.
(TIF)
Figure S11 Determination of GD3S assay unspecificity. As
negative control for the GD3S assay we used ganglioside GM2.
Compared to the positive control using ganglioside GM3, GM2
was unable to stimulate GD3S. Only a background signal is
obtained.
(TIF)
Table S1 Rowdata obtained from quantitative Real-Time PCR
experiments. Tables display all DCt values, DDCt values and
2
2(DDCt) normalized to mRNA actin levels as described in Livak
and Schmittgen [72]. At least three independent RNA prepara-
tions of at least three different brains or cell culture dishes were
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